Method for treating and/or preventing retinal diseases with substained release corticosteroids

• US 20030021828A1
• Filed: 09/25/2002
• Published: 01/30/2003
• Est. Priority Date: 03/22/1999
• Status: Abandoned Application

• Current Assignee: Control Delivery Systems Inc. (EyePoint Pharmaceuticals, Inc.)
• Original Assignee: Control Delivery Systems Inc. (EyePoint Pharmaceuticals, Inc.)
• Inventors: Guo, Hong, Ashton, Paul
• Application Number:
  US10/253,825
• Publication Number:
  US 20030021828A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.

Claims

1. A method for administering a corticosteroid to a posterior segment of an eye, the method comprising the step of:

implanting a sustained release device to deliver the corticosteroid to the vitreous of the eye and wherein aqueous corticosteroid concentration is less than vitreous corticosteroid concentration during release.

2. A method according to claim 1, wherein aqueous corticosteroid concentration is about 0.002 μ

g/ml to about 0.01 μ

g/ml.

3. A method according to claim 2, wherein aqueous corticosteroid concentration is about 0.01 μ

g/ml to about 0.05 μ

g/ml.

4. A method according to claim 1, wherein aqueous corticosteroid concentration is non-toxic and is less than 0.05 μ

g/ml.

5. A method according to claim 1, wherein the device releases corticosteroid for about 1 month to about 10 years.

6. A method according to claim 5, wherein the device releases corticosteroid for about 6 months to about 5 years

7. A method according to claim 1, wherein the vitreous corticosteroid concentration is therapeutic.

8. A method according to claim 1, wherein the vitreous corticosteroid concentration is less than about 10 μ

g/ml.

9. A method according to claim 1, wherein the corticosteroid is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

10. A method according to claim 1, comprising intravitreally implanting the sustained release device.

11. A method according to claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

12. A method according to claim 1, wherein the sustained release device releases the corticosteroid with pseudo zero order kinetics.

13. A method according to claim 1, wherein the sustained release device has a mean release rate of about 1 μ

g/day to about 50 μ

g/day of corticosteroid.

14. A method according to claim 13, wherein sustained release device has a mean release rate of about 1 μ

g/day to about 10 μ

g/day of corticosteroid.

15. A method according to claim 1, wherein the sustained release device releases only one drug.

16. An implantable, sustained release device for administering a corticosteroid to a posterior segment of an eye, the device comprising:

a corticosteroid, wherein the device is configured to provide sustained release of the corticosteroid to the vitreous of the eye such that aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during the release.